Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.48 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170198 | 0.90 | KDM4E (0.74) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL9620029 | 0.85 | KDM4E (0.80) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL6169066 | 0.82 | HCRTR1 (0.56) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL16598906 | 0.81 | SMN1; SMN2 (0.61) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL7795891 | 0.80 | HCRTR1 (0.53) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL11148656 | 0.80 | HCRTR1 (0.53) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL11824061 | 0.80 | SIRT2 (0.56) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL2923502 | 0.79 | SMN1; SMN2 (0.78) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 | |
| SCHEMBL12393020 | 0.79 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL12393006 | 0.79 | HRH3 (0.56) | KDM4EALDH1A1HPGDHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233797-B1 | MAP4K4 (HGK) INHIBITORS | Sri int inc (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10000451-B2 | MAP4K4 (HGK) inhibitors | SRI INTERNATIONAL (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170320824-A1 | MAP4K4 (HGK) Inhibitors | SRI INTERNATIONAL (US) | 2017-11-09 | — | — | US | disclosed |
| EP-3233797-A1 | MAP4K4 (HGK) Inhibitors | SRI International Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016114816-A1 | MAP4K4 (HGK) Inhibitors | SRI INTERNATIONAL (US) | 2016-07-21 | — | — | WO | disclosed |
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | KDM4E 2132/4885ALDH1A1 487/4885HPGD 223/4885 |
| US-20170320824-A1 | MAP4K4 (HGK) Inhibitors | MAP4K4, MAP4K2, MAP4K3 | KDM4E 971/4885ALDH1A1 2488/4885HPGD 1340/4885 |
| US-10000451-B2 | MAP4K4 (HGK) inhibitors | MAP4K4, MAP4K2, MAP4K3 | KDM4E 971/4885ALDH1A1 2488/4885HPGD 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.